Clinical trials with a TLR4 antagonist [93–95] and TNF-α inhibitor [96] have shown no improvement of the mortality rate of severe sepsis patients; however, those trials did not examine long-term muscle function [93–96]. The gene discussed is TLR4; the disease is Sepsis.